Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay

BACKGROUND: Although recent advances in immunotherapy have transformed the treatment landscape for many anatomically defined cancers, these therapies are currently not approved for patients diagnosed with cancer of unknown primary (CUP). Molecular cancer classification using gene expression profilin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Raghav, Kanwal, Overman, Michael, Poage, Graham M., Soifer, Harris S., Schnabel, Catherine A., Varadhachary, Gauri R.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2020
Matèries:
Brief Communications
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648339/
https://ncbi.nlm.nih.gov/pubmed/32893931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0234
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars